BrainStorm Cell Therapeutics Faces Major Setback with Nasdaq Dispute

BrainStorm Cell Therapeutics Faces Major Setback

BrainStorm Cell Therapeutics Inc. (BCLI) shares plummeted by 42.74% to $0.67 in after-hours trading on Friday following the company's announcement of its voluntary delisting from the Nasdaq Capital Market. This significant drop has raised concerns among investors and the larger biotechnology community.

The Delisting Announcement

BrainStorm officially announced it received a formal notification from The Nasdaq Stock Market LLC indicating that its common stock would be suspended from trading at market open on Friday. The delisting is mainly due to the company's failure to comply with the Nasdaq Listing Rule 5550(b)(1), which stipulates that companies must maintain a minimum amount of shareholder equity.

Year-to-Date Performance

Year-to-date, BrainStorm's stock has witnessed a decline of approximately 45.33%. The stock closed at $1.17 on Thursday prior to the after-hours selloff, reflecting the downward trend this year. Following the delisting, the company has gained approval to trade on the OTCQB Venture Market, utilizing the same BCLI ticker symbol effective immediately.

CEO's Assurance to Stakeholders

In a statement, CEO Chaim Lebovits reassured shareholders and the patient community saying, “While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission.” BrainStorm expressed its ongoing commitment to developing its lead investigational therapy, NurOwn, which targets amyotrophic lateral sclerosis (ALS).

Continued Focus on ALS Treatment

BrainStorm's operations and research endeavors remain intact despite the delisting, reinforcing the company's commitment to its innovative treatments. The proprietary NurOwn platform employs autologous adult stem cells to produce neurotrophic factor-secreting cells designed specifically for ALS patients. This therapy holds Orphan Drug designation from both the FDA and the European Medicines Agency, highlighting its potential therapeutic value.

Planned Clinical Trials

Moving forward, BrainStorm completed a Phase 3 ALS trial and plans to initiate a Phase 3b trial under a Special Protocol Assessment agreement with the FDA. Additionally, the company has undertaken a Phase 2 trial for progressive multiple sclerosis, backed by a grant from the National MS Society.

Market Impact and Investment Opportunities

Market analysts view the recent events as pivotal for BrainStorm. Despite the setback, the company's short-term price trend remains positive according to recent evaluations. Investors are advised to remain vigilant regarding future developments and the company's plans moving forward.

Frequently Asked Questions

What caused BrainStorm's stock to drop significantly?

The stock dropped significantly due to the announcement of its voluntary delisting from the Nasdaq Capital Market following non-compliance with specific listing rules.

What is the core mission of BrainStorm Cell Therapeutics?

BrainStorm is focused on developing therapies for neurodegenerative diseases, particularly through its lead investigational therapy for ALS known as NurOwn.

Where can BrainStorm shares be traded after the delisting?

Following the delisting from Nasdaq, BrainStorm shares are now trading on the OTCQB Venture Market under the same BCLI ticker symbol.

What does the CEO say about the company's future?

CEO Chaim Lebovits stated that the core mission of the company remains unchanged despite the delisting, ensuring continued dedication to ALS treatment.

What regulatory designations has NurOwn received?

NurOwn has received Orphan Drug designation from both the FDA and the European Medicines Agency, indicating its significant potential for patients with ALS.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.